| Dr Baptiste S Marino, MD | |
|
1212 Mann Drive, Meidcal Suite 200, Matthews, NC 28105 | |
| (704) 841-0992 | |
| (877) 546-5252 |
| Full Name | Dr Baptiste S Marino |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 38 Years |
| Location | 1212 Mann Drive, Matthews, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104070820 | NPI | - | NPPES |
| 8950665 | Medicaid | NC |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ubylee Healthcare Group | 8921349044 | 8 |
News Archive
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
There's good news for kids with epilepsy. While several new drugs have come out in the last several years for adults with epilepsy, making those drugs available for children and teenagers has been delayed due to the challenges of testing new drugs on children.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
A new study sheds light on the prevalence of insomnia symptoms among female veterans. Results demonstrate that more than 47 percent of female veterans reported symptoms of insomnia that resulted in functional impairment. Of this sample group, less than one percent had a diagnosis of a sleep disorder based on medical records.
› Verified 6 days ago
| Entity Name | Ubylee Healthcare Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265942403 PECOS PAC ID: 8921349044 Enrollment ID: O20190417002402 |
News Archive
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
There's good news for kids with epilepsy. While several new drugs have come out in the last several years for adults with epilepsy, making those drugs available for children and teenagers has been delayed due to the challenges of testing new drugs on children.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
A new study sheds light on the prevalence of insomnia symptoms among female veterans. Results demonstrate that more than 47 percent of female veterans reported symptoms of insomnia that resulted in functional impairment. Of this sample group, less than one percent had a diagnosis of a sleep disorder based on medical records.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Baptiste S Marino, MD Po Box 1707, Matthews, NC 28106-1707 Ph: (336) 240-3500 | Dr Baptiste S Marino, MD 1212 Mann Drive, Meidcal Suite 200, Matthews, NC 28105 Ph: (704) 841-0992 |
News Archive
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
There's good news for kids with epilepsy. While several new drugs have come out in the last several years for adults with epilepsy, making those drugs available for children and teenagers has been delayed due to the challenges of testing new drugs on children.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
A new study sheds light on the prevalence of insomnia symptoms among female veterans. Results demonstrate that more than 47 percent of female veterans reported symptoms of insomnia that resulted in functional impairment. Of this sample group, less than one percent had a diagnosis of a sleep disorder based on medical records.
› Verified 6 days ago